Corbus Pharma doubles as cancer therapy shows promise in early-stage trial

Corbus Pharmaceuticals Holdings

26/01/2024 14:47

** Shares of Corbus Pharmaceuticals  CRBP.O  more than
double to an over 2-year high to $19.27 in early trade
    ** Drug developer says its experimental cancer therapy
CRB-701 reduced tumors by up to 43% in an early-stage study on
patients with bladder cancer as well other cancer tumors with
nectin-4 protein
    ** There have been no dose discontinuations or reductions in
the study to date - CRBP
    ** Stock up four folds in the last 12 months

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))